Eikon announced itself in 2021 with former Merck & Co. exec Roger Perlmutter, M.D., Ph.D., at the helm and quickly ...

Belgian biotech Agomab Therapeutics and eye-focused drug delivery company SpyGlass Pharma both headed to the Nasdaq this ...

The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is ...

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind ...

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to ...

The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity ...

Unprofitable biotech Veradermics, which still needs FDA approval for its hair loss pill, surged on its debut day.

Across all industries, the total number of companies on track to go public could make this week the most active for IPOs ...

Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...

The crop protection chemical maker FMC has retained financial and legal advisers to conduct a strategic review that may lead ...

Biotech firm Eikon Therapeutics raises $381M in an oversubscribed IPO. The cancer & neurology drugmaker is the third successful biotech offering of 2026.